Last reviewed · How we verify
QazCoVac-P -COVID-19 Subunit Vaccine
QazCoVac-P -COVID-19 Subunit Vaccine is a Biologic drug developed by Research Institute for Biological Safety Problems. It is currently in Phase 1 development.
At a glance
| Generic name | QazCoVac-P -COVID-19 Subunit Vaccine |
|---|---|
| Sponsor | Research Institute for Biological Safety Problems |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QazCoVac-P -COVID-19 Subunit Vaccine CI brief — competitive landscape report
- QazCoVac-P -COVID-19 Subunit Vaccine updates RSS · CI watch RSS
- Research Institute for Biological Safety Problems portfolio CI
Frequently asked questions about QazCoVac-P -COVID-19 Subunit Vaccine
What is QazCoVac-P -COVID-19 Subunit Vaccine?
QazCoVac-P -COVID-19 Subunit Vaccine is a Biologic drug developed by Research Institute for Biological Safety Problems.
Who makes QazCoVac-P -COVID-19 Subunit Vaccine?
QazCoVac-P -COVID-19 Subunit Vaccine is developed by Research Institute for Biological Safety Problems (see full Research Institute for Biological Safety Problems pipeline at /company/research-institute-for-biological-safety-problems).
What development phase is QazCoVac-P -COVID-19 Subunit Vaccine in?
QazCoVac-P -COVID-19 Subunit Vaccine is in Phase 1.